Institute completed the first phase of the project within the federal program "PHARMA"

Employees of MMBI has successfully completed Phase 1 of the state contract for the implementation of applied research and experimental development in the framework of 2.5 "Preclinical studies of innovative medicines" federal target program "Development of pharmaceutical and medical industry in the Russian Federation for the period up to 2020 and beyond" entitled "Preclinical studies of anticoagulant fucoidan-based drug". A new technology of pharmaceutical substance fucoidan was created and methods of its analysis developed, we developed a set of normative documents for its standardization. Fucoidan substance was prepared for the next step - preclinical studies of its anticoagulant (reducing blood clotting) properties.